SCHEMBL6208638

SCHEMBL6208638

O=C(Nc1cc(F)c(N2C[C@@H]3C(C(=O)Oc4c(F)c(F)c(F)c(F)c4F)[C@@H]3C2)c(F)c1)OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
POLB P06746 1/20 0.41
KDM1A O60341 2/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RCOR1 Q9UKL0 1/20 0.40
ENPP2 Q13822 1/20 0.39
VCP P55072 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477500 0.88 PTGDR2 (0.44) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL6477799 0.88 MGLL (0.47) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL6478512 0.86 RORC (0.45) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL6477573 0.86 MGLL (0.43) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL5300358 0.82 MGLL (0.52) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL4707931 0.82 MGLL (0.47) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL6208407 0.81 KDM1A (0.49) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL6210658 0.81 NPC1 (0.48) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL5283076 0.80 MGLL (0.45) MGLLPTGDR2POLBKDM1AMAOA
SCHEMBL6477870 0.80 RORC (0.50) MGLLPTGDR2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549641-A1 ANTIMICROBIAL 3.1.0 BICYCLIC OXAZOLIDINONE DERIVATIVES Pharmacia & Upjohn Company LLC (US) 2005-07-06 EP disclosed
US-6875784-B2 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-04-05 US disclosed
US-20040127530-A1 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives PHARMACIA & UPJOHN COMPANY 2004-07-01 US disclosed
WO-2004033451-A1 ANTIMICROBIAL [3.1.0] BICYCLIC OXAZOLIDINONE DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127530-A1 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives OXA1L, CYP1B1, MT-CO1 MGLL 3599/4885PTGDR2 3810/4885POLB 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.